立体定向放疗用于初治头颈癌:系统综述与荟萃分析
该系统综述与荟萃分析纳入9项研究共157例初治(既往未治疗)头颈癌患者,评估SBRT的疗效与毒性。1、2、3年局部控制率分别为90.7%、81.8%、73.5%,总生存率分别为75.9%、61.1%、50.0%,晚期3-4级毒性率为3.3%,晚期5级毒性率为0.1%。结论认为SBRT在多数亚部位安全有效,可提供局部区域控制,但需更广泛验证。
要点
- 初治头颈癌SBRT的1年局部控制率为90.7%,3年降至73.5%。
- 1、2、3年总生存率分别为75.9%、61.1%、50.0%。
- 晚期3-4级毒性率3.3%,晚期5级毒性率0.1%。
核心结论
- SBRT用于初治头颈癌在多数亚部位安全有效,可提供局部区域控制,但需更广泛验证以指导适用范围。
研究设计与样本
- 系统综述与荟萃分析,检索Medline(PubMed)、Excerpta Medica Database和Cochrane Library自建库至2020年7月,纳入9项研究共157例初治头颈癌患者。
主要发现
- 1年局部控制率为90.7%(95%CI 80.6%-95.6%),2年为81.8%(67.2%-90.7%),3年为73.5%(40.4%-90.5%)。
- 1年总生存率为75.9%(95%CI 75.1%-76.6%),2年为61.1%(60.3%-61.9%),3年为50.0%(48.8%-51.4%)。
- 晚期3-4级毒性率为3.3%(95%CI 0.2%-10.2%),晚期5级毒性率为0.1%(0.0%-1.0%)。
临床怎么用
- 对于医学上不适合手术或常规放疗的初治头颈癌患者,SBRT可作为提供局部区域控制的选项,但需注意其证据来自小样本研究。
局限性
- 纳入研究仅9项、共157例患者,样本量小,结论需更广泛验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) for de novo (previously untreated) head and neck cancers (HNCs) is increasingly being used in medically unfit patients. A systematic review of SBRT was conducted for previously untreated HNCs. METHODS AND MATERIALS: Medline (PubMed), excerpta medica database, and Cochrane Library databases were queried from inception until July 2020. Comparative outcome data were extracted where available up to 5 years. Results from random-effect models were presented in forest plots, with between-study heterogeneity evaluated by I2 statistics and Q-tests. RESULTS: Nine studies met inclusion criteria, representing 157 patients. Local control rates at 1, 2, and 3 years were as follows: 90.7% (95% confidence interval, 80.6%-95.6%), 81.8% (67.2%-90.7%), and 73.5% (40.4%-90.5%), respectively. Overall survival at 1, 2, and 3 years was 75.9% (75.1%-76.6%), 61.1% (60.3%-61.9%), and 50.0% (48.8%-51.4%), respectively. Late grade 3 to 4 toxicity rate was 3.3% (0.2%-10.2%), and late grade 5 toxicity rate was 0.1% (0.0%-1.0%). CONCLUSIONS: SBRT for de novo HNC is safe and effective in providing locoregional control, with acceptable toxicities in most subsites. This finding warrants broader validation to guide its scope.
引用
- Malik NH, Kim MS, Chen H, et al. Stereotactic Radiation Therapy for De Novo Head and Neck Cancers: A Systematic Review and Meta-Analysis. Adv Radiat Oncol. 2020. PMID: 33665492. doi:10.1016/j.adro.2020.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。